Sigilon Therapeutics, Inc.

SGTX · NASDAQ
Analyze with AI
6/30/2023
3/31/2023
12/31/2022
9/30/2022
Operating Activities
Net Income-$7,506-$7,378-$6,685-$8,671
Dep. & Amort.$310$315$315$316
Deferred Tax$205$0$0$0
Stock-Based Comp.$1,559$1,349$1,210$1,342
Change in WC$289-$6,716-$3,044-$3,898
Other Non-Cash$987$1,028$987$923
Operating Cash Flow-$4,156-$11,402-$7,217-$9,988
Investing Activities
PP&E Inv.-$139-$351-$25-$6
Net Acquisitions$0$0$0$0
Inv. Purchases-$6,892$0$42,524-$1,484
Inv. Sales/Matur.$6,875$12,589$18,000$9,750
Other Inv. Act.$48$0-$42,471$8
Investing Cash Flow-$108$12,238$18,028$8,268
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$25$61$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$17,369-$1,642-$1,667$13
Financing Cash Flow-$17,369-$1,642-$1,667$13
Forex Effect$0$0$0$0
Net Chg. in Cash-$21,633-$806$9,144-$1,707
Supplemental Information
Beg. Cash$42,544$43,350$34,206$35,913
End Cash$20,911$42,544$43,350$34,206
Free Cash Flow-$4,295-$11,753-$7,242-$9,994
Sigilon Therapeutics, Inc. (SGTX) Financial Statements & Key Stats | AlphaPilot